Overview

Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions

Status:
Active, not recruiting

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AIDS Malignancy Consortium

Collaborators:

National Cancer Institute (NCI)
The Emmes Company, LLC
The EMMES Corporation
University of Arkansas
University of California, San Francisco

Treatments:

Fluorouracil
Imiquimod